CVS Health is dropping the price of an online weight-loss consultation to $29, a move that puts the country’s largest pharmacy chain into direct price competition with the drugmakers and telehealth startups now selling GLP-1 access straight to consumers.
The Woonsocket, Rhode Island company announced the overhaul of its weight management program Tuesday, positioning the $29 MinuteClinic online visit as a first step for eligible adults who want a clinical evaluation for GLP-1 therapy. The visits run around the clock, and CVS says there is no separate membership requirement and no recurring monthly fee attached.
The new price is a meaningful cut. MinuteClinic had been charging $49 for the same cash-pay weight-loss consultation, which covers the consultation itself and does not include the cost of any required lab work.
The Lilly Piece
Alongside the price cut, CVS is teaming with Eli Lilly on distribution. By the early part of the fourth quarter, the company says patients prescribed Zepbound or Foundayo will be able to see transparent pricing, including cash-pay figures, inside the CVS Health app and arrange pickup as soon as the same day at stores nationwide.
That is the strategic heart of the announcement. Patients can meet a licensed clinician online, receive a prescription where clinically appropriate, and collect the medication at one of more than 9,000 CVS Pharmacy locations — a loop that keeps the consultation, the fill and the follow-up support inside CVS.
On out-of-pocket cost, the company laid out several tracks. Eligible patients with commercial insurance using manufacturer coupons may pay as little as $25 a month, while those without insurance can get qualifying medications and doses for $149 a month through manufacturer vouchers. CVS is also participating in the Medicare GLP-1 Bridge program run by the Centers for Medicare and Medicaid Services, which lets qualifying beneficiaries obtain certain GLP-1 drugs for $50 a month through the end of 2027.
Sid Tenneti, senior vice president and interim president of pharmacy and consumer wellness, framed the changes around removing obstacles that stop people before treatment ever begins. The company’s argument is that combining the clinic, the pharmacy counter and the app in one place beats a patchwork of separate vendors.
Why $29 Matters
The number itself is small. The signal is not.
For most of the past two years, the economics of weight-loss medication have been controlled by the manufacturers and by a handful of venture-funded telehealth companies. Lilly sells Zepbound single-dose vials at roughly $299 a month through its own LillyDirect platform, and Novo Nordisk has pushed self-pay Wegovy pricing to levels that would have been implausible a year and a half ago. Novo’s NovoCare program opens at $199 for introductory months before stepping up to $349, and Costco’s arrangement with Sesame prices Wegovy near $349 while requiring a paid membership.
Those consultation fees have been the quiet variable. Telehealth visits through manufacturer partner networks typically run $25 to $99 depending on the partner, and advertised monthly prices frequently exclude consultation charges, membership surcharges, shipping and supply fees that turn a headline number into something considerably larger.
By pricing the visit at $29 with no subscription attached, CVS is attacking the fee layer rather than the drug price — the piece it actually controls. It is also using a low-margin front door to pull patients toward a pharmacy counter that generates revenue for years.
Retail context explains why the competition is this fierce. List pricing on the branded drugs still runs well above $1,200 a month, and most commercial insurers restrict coverage behind prior authorization and step-therapy requirements. Every dollar shaved off the entry point widens the pool of cash-paying customers.
The Retail Angle
CVS is not moving in isolation. Analysts have been arguing for months that large retailers with pharmacy operations are the natural winners as prescriptions shift toward direct-to-consumer channels — the customer acquisition cost is minimal when the patient is already walking through the door for household goods.
For CVS specifically, the calculation is straightforward. A patient who starts GLP-1 therapy typically stays on it for an extended period, returns monthly, and buys other items on the same trip. The chain has also been leaning on its pharmacists as an in-person support layer, a differentiator no mail-order platform can match.
The open question is whether Lilly and Novo Nordisk continue to route volume through retail partners or keep tightening their own direct channels. Both have built closed pipelines that capture the full margin. Wednesday’s announcement suggests at least one of them sees value in the 9,000-store footprint.
Prescriptions remain subject to clinical evaluation, and the drugs are not appropriate for every patient.
JBizNews Desk | New York
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.